Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hill, A. F
Right arrow Articles by Collinge, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hill, A. F
Right arrow Articles by Collinge, J.
Related Collections
Right arrow Immunology
Right arrow Infectious Diseases
Right arrow Neurology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 66:161-170 (2003)
© 2003 The British Council

Subclinical prion infection in humans and animals

Andrew F Hill and John Collinge

MRC Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, London, UK

Transmission of prion diseases between mammalian species is limited by a so-called ‘species’ or ‘transmission’ barrier. Recognition of prion transmission usually relies on the appearance of clinical symptoms in inoculated animals and the interval between inoculation and appearance of clinical disease is designated incubation period. At some point during this clinically silent period, neuropathological and biochemical changes as well as accumulation of prions in the brain can be detected and this stage can be called preclinical prion disease. Recently, several lines of evidence have suggested that subclinical forms of prion disease exist, in which high levels of infectivity and PrPSc are found in animals that do not develop clinically apparent disease during a normal life-span. Such asymptomatic prion ‘carrier’ states challenge our current understanding of pathogenesis as well as of the molecular basis of barriers to transmission. Subclinical as well as preclinical/clinical prion disease may be relevant when analysing the risk to public health of potential sources of prion exposure.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
G. G. Kovacs and H. Budka
Prion Diseases: From Protein to Cell Pathology
Am. J. Pathol., March 1, 2008; 172(3): 555 - 565.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Webb, T. Lekishvili, C. Loeschner, S. Sellarajah, F. Prelli, T. Wisniewski, I. H. Gilbert, and D. R. Brown
Mechanistic Insights into the Cure of Prion Disease by Novel Antiprion Compounds
J. Virol., October 1, 2007; 81(19): 10729 - 10741.
[Abstract] [Full Text] [PDF]

Home page
 J R Soc InterfaceHome page
P. Clarke, R. G Will, and A. C Ghani
Is there the potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK?
J R Soc Interface, August 22, 2007; 4(15): 675 - 684.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
E. M. Norstrom, M. F. Ciaccio, B. Rassbach, R. Wollmann, and J. A. Mastrianni
Cytosolic Prion Protein Toxicity Is Independent of Cellular Prion Protein Expression and Prion Propagation
J. Virol., March 15, 2007; 81(6): 2831 - 2837.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
I. Paspaltsis, K. Kotta, R. Lagoudaki, N. Grigoriadis, I. Poulios, and T. Sklaviadis
Titanium dioxide photocatalytic inactivation of prions.
J. Gen. Virol., October 1, 2006; 87(Pt 10): 3125 - 3130.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
G. Tamguney, K. Giles, E. Bouzamondo-Bernstein, P. J. Bosque, M. W. Miller, J. Safar, S. J. DeArmond, and S. B. Prusiner
Transmission of Elk and Deer Prions to Transgenic Mice
J. Virol., September 15, 2006; 80(18): 9104 - 9114.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Piening, R. Nonno, M. Di Bari, S. Walter, O. Windl, U. Agrimi, H. A. Kretzschmar, and U. Bertsch
Conversion Efficiency of Bank Vole Prion Protein in Vitro Is Determined by Residues 155 and 170, but Does Not Correlate with the High Susceptibility of Bank Voles to Sheep Scrapie in Vivo
J. Biol. Chem., April 7, 2006; 281(14): 9373 - 9384.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. Jacquemot, C. Cuche, D. Dormont, and F. Lazarini
High Incidence of Scrapie Induced by Repeated Injections of Subinfectious Prion Doses
J. Virol., July 15, 2005; 79(14): 8904 - 8908.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. R. Scott, D. Peretz, H.-O. B. Nguyen, S. J. DeArmond, and S. B. Prusiner
Transmission Barriers for Bovine, Ovine, and Human Prions in Transgenic Mice
J. Virol., May 1, 2005; 79(9): 5259 - 5271.
[Abstract] [Full Text] [PDF]

Home page
 J R Soc InterfaceHome page
P. Clarke and A. C Ghani
Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility
J R Soc Interface, March 22, 2005; 2(2): 19 - 31.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
B. Lunenfeld
Historical perspectives in gonadotrophin therapy
Hum. Reprod. Update, November 1, 2004; 10(6): 453 - 467.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.